Drug Profile
Research programme: molecular chaperone regulators - LadRx Corporation
Latest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator Biorex
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders(Prevention) in Hungary
- 07 May 2010 Preclinical development is ongoing in USA